Rezapkin G - Search Results

1

Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.

Puligedda RD, Kouiavskaia D, Adekar SP, Sharma R, Devi Kattala C, Rezapkin G, Bidzhieva B, Dessain SK, Chumakov K. Puligedda RD, et al. Among authors: rezapkin g. Antiviral Res. 2014 Aug;108:36-43. doi: 10.1016/j.antiviral.2014.05.005. Epub 2014 May 10. Antiviral Res. 2014. PMID: 24824031

2

Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.

Rezapkin G, Martin J, Chumakov K. Rezapkin G, et al. Biologicals. 2005 Mar;33(1):29-39. doi: 10.1016/j.biologicals.2004.11.001. Epub 2005 Jan 27. Biologicals. 2005. PMID: 15713554

3

Repertoire of antibodies against type 1 poliovirus in human sera.

Rezapkin G, Neverov A, Cherkasova E, Vidor E, Sarafanov A, Kouiavskaia D, Dragunsky E, Chumakov K. Rezapkin G, et al. J Virol Methods. 2010 Nov;169(2):322-31. doi: 10.1016/j.jviromet.2010.07.037. Epub 2010 Aug 4. J Virol Methods. 2010. PMID: 20691212

4

Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).

Rezapkin G, Dragunsky E, Chumakov K. Rezapkin G, et al. Biologicals. 2005 Mar;33(1):17-27. doi: 10.1016/j.biologicals.2004.11.003. Biologicals. 2005. PMID: 15713553

5

Determination of poliovirus-specific IgA in saliva by ELISA tests.

Ivanov A, Dragunsky E, Ivanova O, Rezapkin G, Potapova S, Chumakov K. Ivanov A, et al. Among authors: rezapkin g. J Virol Methods. 2005 Jun;126(1-2):45-52. doi: 10.1016/j.jviromet.2005.01.030. J Virol Methods. 2005. PMID: 15847918

6

Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R. Chen Z, et al. Among authors: rezapkin g. J Virol. 2011 May;85(9):4354-62. doi: 10.1128/JVI.02553-10. Epub 2011 Feb 23. J Virol. 2011. PMID: 21345966 Free PMC article.

7

Poliovirus-binding inhibition ELISA for evaluation of immune response to oral poliovirus vaccine: a possible alternative to the neutralization test.

Ivanov AP, Dragunsky EM, Ivanova OE, Rezapkin GV, Potapova SG, Chumakov KM. Ivanov AP, et al. Among authors: rezapkin gv. Hum Vaccin. 2005 May-Jun;1(3):102-5. doi: 10.4161/hv.1.3.1719. Epub 2005 May 5. Hum Vaccin. 2005. PMID: 17012865

8

Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.

Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM. Dragunsky EM, et al. Among authors: rezapkin gv. J Infect Dis. 2004 Oct 15;190(8):1404-12. doi: 10.1086/424524. Epub 2004 Sep 20. J Infect Dis. 2004. PMID: 15378432

9

Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine.

Rezapkin GV, Alexander W, Dragunsky E, Parker M, Pomeroy K, Asher DM, Chumakov KM. Rezapkin GV, et al. Virology. 1998 Jun 5;245(2):183-7. doi: 10.1006/viro.1998.9191. Virology. 1998. PMID: 9636357 Free article.

10

Reevaluation of nucleotide sequences of wild-type and attenuated polioviruses of type 3.

Rezapkin GV, Douthitt M, Dragunsky E, Chumakov KM. Rezapkin GV, et al. Virus Res. 1999 Dec 15;65(2):111-9. doi: 10.1016/s0168-1702(99)00108-2. Virus Res. 1999. PMID: 10581384

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page